1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 20-FREGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIESEXCHANGE ACT OF 1934ORANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGEACT OF 1934For the fiscal year ended December 31,2010ORTRANSI
2、TION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGEACT OF 1934Commission File number:0-16174ORSHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF 1934TEVA PHARMACEUTICAL INDUSTRIES LIMITED(Exact name of Registrant as specified in its charter)Not App
3、licable(Translation of Registrants name into English)ISRAEL(Jurisdiction of incorporation or organization)5 Basel StreetP.O.Box 3190Petach Tikva 49131,Israel(Address of principal executive offices)Eyal DeshehChief Financial OfficerTeva Pharmaceutical Industries Limited5 Basel StreetP.O.Box 3190Petac
4、h Tikva 49131,IsraelTel:972-3-914-8171Fax:972-3-914-8678(Name,telephone,e-mail and/or facsimile number and address of Company contact person)Securities registered or to be registered pursuant to Section 12(b)of the Act.Title of each className of each exchange on which registeredAmerican Depositary S
5、hares,each representing one Ordinary ShareThe Nasdaq Stock Market LLCSecurities registered or to be registered pursuant to Section 12(g)of the Act.None(Title of Class)Securities for which there is a reporting obligation pursuant to Section 15(d)of the Act.None(Title of Class)Indicate the number of o
6、utstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered by the annual report.937,499,245 Ordinary Shares703,806,530 American Depositary SharesIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of t